[go: up one dir, main page]

AU2001290949A1 - Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma - Google Patents

Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma

Info

Publication number
AU2001290949A1
AU2001290949A1 AU2001290949A AU9094901A AU2001290949A1 AU 2001290949 A1 AU2001290949 A1 AU 2001290949A1 AU 2001290949 A AU2001290949 A AU 2001290949A AU 9094901 A AU9094901 A AU 9094901A AU 2001290949 A1 AU2001290949 A1 AU 2001290949A1
Authority
AU
Australia
Prior art keywords
carcinoma
genes
diagnostic
products
types
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290949A
Inventor
Judith Campisi
Pierre-Yves Desprez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
California Pacific Medical Center
Original Assignee
University of California
University of California Berkeley
California Pacific Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley, California Pacific Medical Center filed Critical University of California
Publication of AU2001290949A1 publication Critical patent/AU2001290949A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5751
    • G01N33/57515
    • G01N33/57555
    • G01N33/57557
    • G01N33/5759
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001290949A 2000-09-14 2001-09-14 Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma Abandoned AU2001290949A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23255800P 2000-09-14 2000-09-14
US23252900P 2000-09-14 2000-09-14
US60/232,529 2000-09-14
US60/232,558 2000-09-14
PCT/US2001/028811 WO2002022858A1 (en) 2000-09-14 2001-09-14 Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma

Publications (1)

Publication Number Publication Date
AU2001290949A1 true AU2001290949A1 (en) 2002-03-26

Family

ID=26926089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290949A Abandoned AU2001290949A1 (en) 2000-09-14 2001-09-14 Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma

Country Status (5)

Country Link
US (4) US7429457B2 (en)
EP (1) EP1326996A4 (en)
AU (1) AU2001290949A1 (en)
CA (1) CA2422320A1 (en)
WO (1) WO2002022858A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1326996A4 (en) * 2000-09-14 2005-08-24 Univ California ID-1 AND ID-2 GENES AND PRODUCTS AS DIAGNOSTIC OR PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR THE TREATMENT OF BREAST CANCER AND OTHER TYPES OF CARCINOMA
WO2002044417A2 (en) * 2000-11-28 2002-06-06 Wyeth Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
ES2343318T3 (en) * 2002-11-26 2010-07-28 University Of Massachusetts ARNSIS ADMINISTRATION.
WO2006118564A2 (en) * 2004-04-29 2006-11-09 Washington State University Research Foundation MODIFIED CELLS EXPRESSING A PROTEIN THAT MODULATES ACTIVITY OF bHLH PROTEINS, AND USES THEREOF
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2475183B (en) * 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
AU2011207563B2 (en) * 2010-01-19 2016-03-10 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9254272B2 (en) 2011-11-30 2016-02-09 Sutter West Bay Hospitals Resorcinol derivatives
PT2790737T (en) * 2011-12-12 2019-02-28 Childrens Hospital Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US6048850A (en) 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6372433B1 (en) * 2000-04-28 2002-04-16 Isis Pharmaceuticals, Inc. Antisense modulation of inhibitor of DNA binding-1 expression
EP1326996A4 (en) * 2000-09-14 2005-08-24 Univ California ID-1 AND ID-2 GENES AND PRODUCTS AS DIAGNOSTIC OR PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR THE TREATMENT OF BREAST CANCER AND OTHER TYPES OF CARCINOMA
WO2002044417A2 (en) * 2000-11-28 2002-06-06 Wyeth Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US7267951B2 (en) * 2002-06-05 2007-09-11 Sloan-Kettering Institute For Cancer Research Method for evaluating a tissue or biopsy sample to determine if the sample is early-stage melanoma

Also Published As

Publication number Publication date
US8846629B2 (en) 2014-09-30
US20090180988A1 (en) 2009-07-16
US8809291B2 (en) 2014-08-19
EP1326996A1 (en) 2003-07-16
US7429457B2 (en) 2008-09-30
US20020137064A1 (en) 2002-09-26
US8030012B2 (en) 2011-10-04
CA2422320A1 (en) 2002-03-21
WO2002022858A1 (en) 2002-03-21
US20120021047A1 (en) 2012-01-26
EP1326996A4 (en) 2005-08-24
WO2002022858A9 (en) 2004-04-22
US20060234273A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU1807401A (en) Compositions and methods for therapy and diagnosis of breast cancer
AU2001290949A1 (en) Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU6328196A (en) Targets for breast cancer diagnosis and treatment
AU3391200A (en) Compositions and methods for breast cancer therapy and diagnosis
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2001268467A1 (en) Identification of genes and compounds for treatment of cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
AU2596901A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2003245927A1 (en) Target genes for the diagnosis and treatment of cancer
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.